Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a stake in the Danish drugmaker.Parvus Asset Management is reportedly ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge fund Parvus Asset Management is building a stake in the Danish drugmaker.

Parvus Asset Management is building a stake in Novo Nordisk and hopes to influence its choice of a new CEO. Novo Nordisk itself is preparing to release clinical trial results on CagriSema's ...

Image source: Getty Images. Novo's trial disappoints Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug.

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk amid investor concerns that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss ...

Image source: Getty Images. What's next for Novo Nordisk Novo Nordisk confirmed it is now seeking a successor for Jørgensen, but these are big shoes that need filling.

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building a stake in the Ozempic maker.

That makes Novo Nordisk stock the least risky way to play this trend. Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk.